MIRM Quote, Financials, Valuation and Earnings

Insmed, Inc. has a net margin of 2.18% compared to Mirum Pharmaceuticals, Inc.'s net margin of -259.95%. Mirum Pharmaceuticals, Inc.'s return on equity of -16.73% beat Insmed, Inc.'s return on equity of -193.23%.

Mirum Pharmaceuticals, Inc. has a consensus price target of $114.70, signalling upside risk potential of 14.16%. On the other hand Insmed, Inc. has an analysts' consensus of $215.15 which suggests that it could grow by 43.57%. Given that Insmed, Inc. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe Insmed, Inc. is more attractive than Mirum Pharmaceuticals, Inc..

Mirum Pharmaceuticals, Inc. has a beta of 0.492, which suggesting that the stock is 50.821% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.538%.

Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Mirum Pharmaceuticals, Inc. quarterly revenues are $133M, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Mirum Pharmaceuticals, Inc.'s net income of $2.9M is higher than Insmed, Inc.'s net income of -$370M. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 10.84x versus 63.77x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 2.18% compared to Mirum Pharmaceuticals, Inc.'s net margin of -9.34%. Mirum Pharmaceuticals, Inc.'s return on equity of -16.73% beat Pfizer Inc.'s return on equity of 10.84%.

Mirum Pharmaceuticals, Inc. has a consensus price target of $114.70, signalling upside risk potential of 14.16%. On the other hand Pfizer Inc. has an analysts' consensus of $28.71 which suggests that it could grow by 5.48%. Given that Mirum Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Mirum Pharmaceuticals, Inc. is more attractive than Pfizer Inc..

Mirum Pharmaceuticals, Inc. has a beta of 0.492, which suggesting that the stock is 50.821% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.32% to investors and pays a quarterly dividend of $0.43 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.

Mirum Pharmaceuticals, Inc. quarterly revenues are $133M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Mirum Pharmaceuticals, Inc.'s net income of $2.9M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 20.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 10.84x versus 2.48x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of 2.18% compared to Mirum Pharmaceuticals, Inc.'s net margin of -3135.32%. Mirum Pharmaceuticals, Inc.'s return on equity of -16.73% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

Mirum Pharmaceuticals, Inc. has a consensus price target of $114.70, signalling upside risk potential of 14.16%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 75.88%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Mirum Pharmaceuticals, Inc..

Mirum Pharmaceuticals, Inc. has a beta of 0.492, which suggesting that the stock is 50.821% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Mirum Pharmaceuticals, Inc. quarterly revenues are $133M, which are larger than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Mirum Pharmaceuticals, Inc.'s net income of $2.9M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 10.84x versus 36.51x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of 2.18% compared to Mirum Pharmaceuticals, Inc.'s net margin of 52.48%. Mirum Pharmaceuticals, Inc.'s return on equity of -16.73% beat XOMA Royalty Corp.'s return on equity of 17.31%.

Mirum Pharmaceuticals, Inc. has a consensus price target of $114.70, signalling upside risk potential of 14.16%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 159.45%. Given that XOMA Royalty Corp. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe XOMA Royalty Corp. is more attractive than Mirum Pharmaceuticals, Inc..

Mirum Pharmaceuticals, Inc. has a beta of 0.492, which suggesting that the stock is 50.821% less volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.855, suggesting its less volatile than the S&P 500 by 14.461%.

Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Mirum Pharmaceuticals, Inc. quarterly revenues are $133M, which are larger than XOMA Royalty Corp. quarterly revenues of $9.4M. Mirum Pharmaceuticals, Inc.'s net income of $2.9M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 33.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 10.84x versus 8.65x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.